Soligenix, Inc. — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014; balance-sheet figures are as of June 30, 2014, compared with December 31, 2013. Soligenix is a clinical-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Revenue primarily comes from government grants and contracts, not product sales.
Financial results and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Revenue | $1.418 million | $0.632 million | $2.329 million | $1.533 million |
| Gross profit | $0.384 million | $0.104 million | $0.665 million | $0.261 million |
| Gross margin | 27.1% | 16.5% | 28.6% | 17.0% |
| Operating expenses | $2.079 million | $2.860 million | $3.951 million | $4.105 million |
| Operating loss | $1.696 million | $2.756 million | $3.286 million | $3.844 million |
| Net loss | $0.949 million | $3.405 million | $4.280 million | $4.493 million |
| Net loss per share | $0.05 | $0.28 | $0.22 | $0.38 |
Six-month operating cash use was $1.100 million, versus $1.447 million in the prior-year period. Investing cash use was $42,191; financing provided $327,478, mainly from the Lincoln Park equity facility and option exercises. Cash declined $814,910, or 14%, from year-end to $5.041 million.
Total assets were $6.146 million and current liabilities were $10.810 million. Current liabilities included an $8.774 million warrant liability, a non-cash fair-value obligation. Management reported working capital of $3.534 million after excluding that warrant liability; including it, current assets less current liabilities imply a deficit of approximately $5.240 million. The filing reports no conventional debt balance. Shareholders’ deficiency was $4.664 million.
Material changes and drivers
- Q2 revenue rose 124% and first-half revenue rose 52%, primarily due to progress under OrbeShield government contracts. Gross profit increased as those contracts provided management fees and higher negotiated overhead reimbursement.
- R&D expense declined 43% in Q2 and 23% for the first half. The prior-year comparison included $1.5 million of stock issued under the Intrexon collaboration; current-period spending included the SGX942 Phase 2 trial and increased headcount.
- G&A expense increased 20% in Q2 and 41% for the first half, reflecting higher outside professional-services costs and headcount.
- Q2 net loss improved substantially in part because warrant remeasurement generated $746,992 of non-cash income, compared with a $649,576 non-cash expense in Q2 2013. For the first half, warrant remeasurement was a $995,098 non-cash expense.
- Common shares outstanding rose from 19.626 million at year-end to 20.001 million at June 30, 2014. The company issued shares through its equity line and for services and collaboration-related consideration.
Outlook, risks, and contingencies
- Management believed available cash, government-program proceeds, the Lincoln Park facility and expected New Jersey tax-certificate proceeds would fund working capital and capital expenditures for at least 12 months. This is an estimate dependent on funding and spending assumptions.
- Management forecast approximately $10.9 million of R&D spending over the next 12 months before grant reimbursements ($3.5 million BioTherapeutics and $7.4 million Vaccines/BioDefense), with approximately $7.3 million of expected contract and grant revenue to offset costs.
- Approximately $31.4 million of active contract and grant funding remained available for associated programs through 2015 and beyond. The $10 million Lincoln Park equity facility had approximately $9.7 million available at June 30, 2014, subject to its terms. Further equity financing may be sought; availability and favorable pricing are not assured.
- Key development plans included SGX942 Phase 2 data expected in the second half of 2014 and a planned SGX203 Phase 2/3 trial in the second half of 2014. Several programs and milestones depend on continued government funding, clinical results and regulatory progress.
- OrbeShield BARDA and NIAID contracts could provide up to $26.3 million and $6.4 million, respectively, subject to contract options and conditions. These are not guaranteed amounts of revenue.
- Contractual obligations totaled approximately $436,000 over the disclosed schedule. Separate license and collaboration arrangements may require milestones and royalties upon clinical or commercial success, including Intrexon milestones of up to $7 million.
- Risks include clinical and regulatory failure, reliance on government grants and contracts, need for additional capital and potential dilution, and uncertainty around the fair value of liability-classified warrants. Management identified no additional risk factors beyond those in its 2013 Form 10-K.
Investor verification points
- Confirm the timing, enrollment, funding and subsequent results of the SGX942 trial and the status of planned SGX203 and other clinical programs.
- Check subsequent filings for actual government contract and grant receipts, contract options exercised, and whether expected New Jersey tax-certificate proceeds were received.
- Assess cash burn against management’s 12-month liquidity assertion, including the difference between reported working capital excluding warrants and the current-liability deficit including them.
- Review warrant terms and fair-value assumptions, and monitor changes in warrant liability, share count and use of the Lincoln Park facility for potential dilution.
- Verify whether projected R&D spending and grant reimbursements materialized, and whether any contingent milestones, royalties or additional financing obligations arose.